The role of molecular adsorbent recirculating system in pediatric acute liver failure

Bernabeu, Jesús Quintero; López, Juan Ortega; Goñi, Javier; Tatis, Ecaterina Julio; Mercadal-Hally, María; Aguirre, I. Bilbao; Liria, C. Rodrigo Gonzalo de; Charco, Ramón

doi:10.1002/lt.24966

Cited by 8 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This paper highlights the length of time MARS was used for 20 . MARS was originally intended to be used for approximately 6–8 h; however, in this study, 18 of the cycles were over 8 h long 20 . This shows that MARS can also be used for varying periods of time without consequences to the patient 20 …”

Section: Resultsmentioning

confidence: 89%

“…This study infused heparin into the system for each patient, which was not commonly used in other studies. This paper highlights the length of time MARS was used for 20 . MARS was originally intended to be used for approximately 6–8 h; however, in this study, 18 of the cycles were over 8 h long 20 .…”

Section: Resultsmentioning

confidence: 99%

“…A study by Quintero Bernabeu et al . examined 11 pediatric patients and showed a significant decrease in blood toxins in patients with ALF 20 . This study infused heparin into the system for each patient, which was not commonly used in other studies.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Artificial liver support systems

Tandon

Froghi

2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Artificial liver systems are used to bridge between transplantation or to allow a patient's liver to recover. They are used in patients with acute liver failure (ALF) and acute‐on‐chronic liver failure. There are five artificial systems currently in use: molecular adsorbent recirculating system (MARS), single‐pass albumin dialysis (SPAD), Prometheus, selective plasma filtration therapy, and hemodiafiltration. The aim is to compare existing data on the efficiency of these devices. A literature search was conducted using online libraries. Inclusion criteria included randomized control trials or comparative human studies published after the year 2000. A systematic review was conducted for the five individual devices with a more detailed comparison of the biochemistry for the SPAD and MARS systems. Eighty‐nine patients were involved in the review comparing SPAD and MARS. Results showed that there was an average reduction in bilirubin (−53 μmol/L in MARS and −50 μmol/L in SPAD), creatinine (−19.5 μmol/L in MARS and −7.5 μmol/L in SPAD), urea (−0.9 mmol/L in MARS and −0.75 mmol/L in SPAD), and gamma‐glutamyl transferase (−0.215 μmol/L·s in MARS and −0.295 μmol/L·s in SPAD) in both SPAD and MARS. However, there was no significant difference between the changes in the two systems. This review demonstrated that both MARS and SPAD aid recovery of ALF. There is no difference between the efficiency of MARS and SPAD. Because of the limited data, there is a need for more randomized control trials. Evaluating cost and patient preference would aid in differentiating the systems.

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Artificial liver support systems

Tandon

Froghi

2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Shaefer et al comparan pacientes tratados con MARS vs plasmaféresis y hemodiálisis, encontrando mejoría de la coagulopatía y mayor eficacia en la remoción de toxinas hidrosolubles y unidas a albumina en el último grupo 30 . Bernabéu y su grupo emplearon MARS en pacientes con EH II o mayor, insuficiencia hepatorrenal o intoxicación medicamentosa susceptible de ser aclarada con este sistema, hubo disminución en la concentración de toxinas hidrosolubles y unidas a proteínas 31 .…”

Section: Soporte Hepático Extracorpóreounclassified

Falla hepática aguda en pediatría

Cárdenas

Rivera

Correa³

2020

Rev Chil Pediatr

View full text Add to dashboard Cite

La falla hepática aguda (FHA) es poco frecuente en pediatría, amenaza la vida y requiere abordaje multidisciplinario para su diagnóstico y tratamiento tempranos. El presente artículo tiene como objetivo realizar actualización de definiciones, enfoques y tratamientos disponibles. Los artículos se obtuvieron de la revisión de la literatura disponible entre 2000 y 2020 en varias bases de datos (Pubmed, LILACS, BIREME, Google Académico y UpToDate), empleando términos “acute liver failure” en Pubmed, “pediatric acute liver failure”, “falla hepática aguda en pediatría” para otros buscadores y aplicando filtros según edad, fecha de publicación y tipo de estudio (ensayos clínicos, artículos de revisión, revisiones sistemáticas, estudios de casos y controles), se eligieron aquellos artículos con mayor número de citaciones y con datos recientes. La FHA requiere soporte en cuidado intensivo pediátrico y su diagnóstico temprano favorece la instauración del tratamiento. Se recomienda el enfoque de pruebas diagnósticas específicas por edad en pacientes pediátricos con FHA. No hay consenso acerca de las indicaciones de trasplante hepático en FHA en pediatría.

show abstract

Cellular and Non-Cellular Liver Assist Devices in Management of Acute and Acute on Chronic Liver Failure

Stange

2020

Liver Failure

View full text Add to dashboard Cite

The role of molecular adsorbent recirculating system in pediatric acute liver failure

Cited by 8 publications

References 4 publications

Artificial liver support systems

Artificial liver support systems

Falla hepática aguda en pediatría

Cellular and Non-Cellular Liver Assist Devices in Management of Acute and Acute on Chronic Liver Failure

Contact Info

Product

Resources

About